Abstract:ID 87867 Poster Board 474 The combined inhibition of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) represents a novel approach to non-opioid pain management, drawing from the known functions of these enzymes in pain and inflammatory pathways. Using multi-target directed ligands (MTDLs), a medicinal chemistry approach where a single drug modulates two or more biological targets simultaneously, our lab previously identified several benzothiazole-phenyl MTDLs with potent dual sEH and FAAH inhibition. Here, we report several in vivo evaluations of our previously identified dual sEH/FAAH inhibitor SP 4-5, the data received from National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP) and a follow-up structure-activity relationship (SAR) study of quinolinyl-phenyl-based MTDLs that were synthesized using a microwave-assisted Suzuki coupling reaction. SP 4-5 was evaluated against persistent inflammatory pain. An intraplantar injection of Complete Freund's Adjuvant (CFA) was used to induce hindpaw inflammation. 1 and 3 mg/kg SP4-5 were administered 24 hours after inflammation. Neither dose alleviated mechanical or thermal hypersensitivity. However, when administered 2.5 hours after CFA, 3 mg/kg SP4-5 increased mechanical withdrawal thresholds indicating antinociception. In addition, PDSP screening showed that SP 4-5 does not bind to delta, mu and kappa opioid receptors. Our SAR study showed that quinoline moiety can successfully replace benzothiazole ring yielding potent compounds in human FAAH and human, rat, and mouse sEH inhibition assays. The most potent dual sEH/FAAH inhibitor identified in this study, JA112, showed inhibition potency in the low nanomolar range (1.7 nM -17.2 nM) for human FAAH, human sEH, rat sEH and mouse sEH enzymes. JA-112 was evaluated for its ability to reverse acute inflammatory induced by an intraplantar injection of dilute formalin. This revealed that JA-112 produces antinociception against formalin-induced inflammatory pain. Further, the differences observed between Phase 1 and Phase 2 of the Formalin Test indicate that JA-112 produces antinociception in a manner consistent with drugs that prevent pro-inflammatory states such as non-steroidal anti-inflammatory drugs (i.e., in non-opioid manner). Future experiments will investigate the effects of JA-112 against persistent inflammatory pain states and determine any adverse effects. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1 R16GM149204-01.

Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase

Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

Clickable, Photoreactive Inhibitors to Probe the Active Site Microenvironment of Fatty Acid Amide Hydrolase().

Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

The Covalent Reactivity of Functionalized 5-Hydroxy-butyrolactams is the Basis for Targeting of Fatty Acid Binding Protein 5 (FABP5) by the Neurotrophic Agent MT-21

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Multitarget-Directed Ligands with Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Inhibitory Activities for Treatment of Chronic Pain

Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([¹¹C]MPPO) Based on α-Ketoheterocyclic Scaffold

From Hit to Lead: Structure-based Discovery of Naphthalene-1-sulfonamide Derivatives As Potent and Selective Inhibitors of Fatty Acid Binding Protein 4.

Synthesis of phenoxyacyl-ethanolamides and their effects on fatty acid amide hydrolase activity

Highly Selective Inhibitors of Monoacylglycerol Lipase Bearing a Reactive Group that Is Bioisosteric with Endocannabinoid Substrates

Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-chloro-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)pip Erazine and 1-(3-bromo-8-chloro-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridin-1 1-Yl)piperazine

Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands

Structural analysis of a plant fatty acid amide hydrolase provides insights into the evolutionary diversity of bioactive acylethanolamides

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Sulfonamide Moiety As Novel FAK Inhibitors

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

Role of Steroids on the Membrane Binding Ability of Fatty Acid Amide Hydrolase